The mechanism by which treatment with thrombolytic agents causes bleeding is not known. Recently, frequency of bleeding events has been shown to correlate with bleeding time, particularly in individuals treated with aspirin. We examined the effects of streptokinase (20,000-60,000 IU/kg) on bleeding time in 40 rabbits pretreated with aspirin, a model for fibrinolytic therapy. We then tested the effects of 1-desamino-8-D-arginine vasopressin (DDAVP) (0.3 ug/kg), an agent known to reduce bleeding time in a variety of bleeding disorders, in 20 rabbits and compared the results with those of a control group of rabbits receiving normal saline placebo. Aspirin increased the bleeding time from a baseline mean+SEM value of 119±15 to 191±34 seconds in the control group and from 114±6 to 188+18 seconds in the experimental group. The addition of streptokinase increased the bleeding time to 592±119 seconds in the control group and 810±114 seconds in the experimental group (p=NS). Subsequent infusion of DDAVP decreased the bleeding time in the experimental group to 302 ±29 seconds (p <0.01 versus streptokinase) compared with 572±79 seconds (p=NS versus streptokinase) in the control animals given saline placebo. In a subset of rabbits receiving aspirin and streptokinase (40,000-60,000 IU/kg), samples were obtained for platelet aggregation (n = 16), von Willebrand factor antigen concentration (n= 17), and von Willebrand factor multimer distribution (n= 14). Maximal rates of ADP-induced platelet aggregation were not affected by DDAVP infusion, nor was the plasma concentration of von Willebrand factor antigen, quantified by an immunoradiometric assay, significantly affected by DDAVP infusion. Furthermore, the von Willebrand factor multimer ratio decreased with DDAVP administration. These findings indicate that aspirin and streptokinase combined result in a marked increase in bleeding time that can be reduced by DDAVP. This effect of DDAVP is not accompanied by an increase in platelet aggregation response, plasma von Willebrand factor antigen concentration, or von Willebrand factor multimer ratio. (Circulation 1990;82:2142-2151 From the Division of Cardiology Center for Research in Thrombolysis (M.T.J., T.A., M.A.R., D.G., J.L.), Brigham and Women's Hospital, the Cardiology Section (J.L.), Brockton/West Roxbury
T ohrombolysis has become an important therapeutic modality for acute myocardial infarction. Clinical studies have shown that dissolution of a clot in an infarct-related artery leads to preservation of the myocardium and decreased mortality rates. Unfortunately, the benefits of thrombolytic therapy are limited by an inability to achieve timely reperfusion, by significant rates of reocclusion, and by bleeding complications. In individuals under-going invasive procedures, administration of tissuetype plasminogen activator (t-PA) and streptokinase is complicated by major bleeding episodes in 4% and 1% of treated patients, respectively.' Although some reports have suggested a correlation between bleeding complications and fibrinogen decrease, the relation is apparent only on average as no correlation between extent of bleeding and decrement in fibrinogen has been observed within individual patients. 2 The routine use of aspirin in patients treated with thrombolytics for acute myocardial infarction further complicates the risks and benefits to which these patients are subjected. The results of the ISIS-2 trial demonstrated that aspirin therapy improves the survival rates of patients receiving only streptokinase. 3 However, Gimple and coworkers4 recently demonstrated that the combined use of aspirin with thrombolytics can result in a prolongation of the bleeding time that correlates strongly with bleeding risk.
The use of any agent that can reduce bleeding time may in turn reduce bleeding complications. 1-Desamino-8-D-arginine vasopressin (DDAVP) is a vasopressin analogue used in the treatment of many bleeding disorders, including von Willebrand's disease and platelet storage pool disorders. 5 In these and other clinical disorders in which there are no known abnormalities of von Willebrand factor, DDAVP has been shown to reduce bleeding time and blood loss. In the present study, we examine the effects of the combined use of aspirin and streptokinase on bleeding times in the rabbit and investigate the effect of DDAVP on subsequent bleeding time prolongation. Methods 
Reagents
Acetylsalicylic acid (aspirin) was dissolved in autologous rabbit plasma and administered to rabbits at doses sufficient to achieve a level of 5.1±2.1 mg/dl aspirin in serum. Lyophilized streptokinase (Streptase 375,000 IU/ml; Hoescht Roussel, Somerville, N.J.) was dissolved in 2 ml of distilled water before infusion. DDAVP (Stimate 4 gg/ml; Armour Pharmaceutical, Kankakee, Ill.) was used at a dose of 0.3 ,gg/kg. Aprotinin, fatty acid-free bovine serum albumin (BSA), sodium dodecyl sulfate (SDS), and EDTA were purchased from Sigma Chemical Co., St. Louis. Na[1251] was obtained from New England Nuclear, Boston. Polyclonal goat F(ab')2 anti-human von Willebrand antibody was purchased from American Diagnostica, Greenwich, Conn. IODOGEN was obtained from Pierce Chemical Co., Rockford, Ill. Immulon II microtiter strips were purchased from Dynatech, Inc, Chantilly, Va. ME agarose gel was obtained from F.M.C., Rockland, Me.
Animal Preparation and Protocol
Forty female New Zealand White rabbits (2-4 kg) were initially anesthetized with 30-50 mg/kg i.v. ketamine (Ketalar; Parke-Davis, Morris Plains, N.J.). Pentobarbitol (Nembutal sodium; Abbott, North Chicago.) was given subsequently (30-50 mg/kg) to maintain the anesthetized state (Figure 1 ). The femoral artery and vein were then exposed and cannulated.
After baseline bleeding times were obtained (as described below), aspirin dissolved in autologous plasma was injected into the rabbit through the femoral vein. After a 1-hour period, bleeding times were repeated. Streptokinase was then infused at 20,000, 40,000, or 60,000 IU/kg/hr for 1 hour. In selected rabbits with normal bleeding times (<5 minutes), a second streptokinase dose was given over 1 hour after the first streptokinase dose. Dosages and experimental protocols are given in Tables 1 and 2 . After 1 hour, during which bleeding times were repeated, normal saline or DDAVP (0.6 gg/kg/hr) was infused. In selected experiments, bleeding times were measured by observers blinded as to whether normal saline or DDAVP was administered (indicated by "x" in Tables 1 and 2) . At the completion of the experiment, the animals were killed, and autopsies were performed. Blood samples were taken at the start of the experiment, 1 hour after the initiation of aspirin, streptokinase, and DDAVP infusions. At each time point, two 1-ml blood samples were drawn into two syringes -one containing a final concentration of 13 mM trisodium citrate and one containing a final concentration of 13 mM trisodium citrate plus 250 KIU/ml aprotinin. Platelet counts and hematocrits were determined from tube 1, whereas tube 2 was immediately spun at 3,000g, and the supernatant was frozen at -70°C to assess fibrinogen levels at a later time. Samples for aspirin levels were drawn separately 1 hour after aspirin infusion. In a subset of rabbits, 3 -ml samples for von Willebrand factor were collected in syringes containing 13 mM trisodium citrate plus 250 KIU/ml aprotinin.
Bleeding Times
Bleeding time was measured using two previously described techniques-the rabbit ear method6 and the template method.7 In the first method, a shaved rabbit ear was placed for 5 minutes into a stirred beaker of normal saline heated to 370 C to warm the ear. The ear was then removed from the beaker, and a full-thickness incision was made through the ear with a 15 stainless-steel surgical blade (Parker Becton Dickinson and Co., Lincoln Park, N.J.) in a transverse direction, avoiding any macroscopically visible vessels. The ear was then placed into the saline bath and observed until all blood flow had ceased, with care taken to not move or bend the ear during the observation period.
In the second method, the medial aspect of the noncatheterized upper hind leg was closely shaved for serial template bleeding determinations using a singleblade, spring-loaded device (Simplate General Diagnostics, Morris Plains, N.J.). The standardized incision (5 mm long and 1 mm deep) was made parallel to the long axis of the limb, and care was taken to avoid the superficial veins. The incision sites were blotted at 30-second intervals with filter paper, avoiding direct contact with the wound. The bleeding time was defined as the time interval from incision until blood no longer stained the blotting filter paper. Five rabbits had bleeding times measured by both methods. The bleeding times of each method were compared, and a regression analysis was performed, yielding a correlation coefficient (r) of 0.97 (p<0.0001; y is template bleeding time, and x is ear bleeding time, in seconds). Thus, the two methods were directly comparable. 
Plasma Fibrinogen Determination
Plasma fibrinogen determinations were made using the sodium sulfite precipitation method of Rampling and Gaffney8 on the timed blood samples collected as described.
yielded bound`251-antibody levels of 12,000-3,000 cpm/gl plate well. Human plasma diluted from 1: 200 to 1: 3,200 gave a similar linear dose-response curve. Thus, quantification of rabbit von Willebrand factor Platelet Preparation and Aggregation Platelet-rich plasma was prepared by centrifuging whole blood at 138g for 10 minutes at 220 C. Platelet counts were determined with a Coulter counter (Model ZM, Coulter Electronics Inc., Hialeah, Fla.). Platelets in platelet-rich plasma were aggregated with 11 ,uM ATP. Aggregation (n=16) was monitored at 370 C while stirring at 900 rpm with a dual-channel aggregometer (Payton Associates, Buffalo, N.Y.) and quantified by measuring the maximal rate of increase in light transmittance after the addition of ADP.
Plasma von Willebrand Factor Antigen and Multimer Distribution
Rabbit von Willebrand factor antigen concentration (n = 17) was quantified by an immunoradiometric assay using iodine-125-labeled polyclonal goat F(ab')2 anti-human von Willebrand factor antibody (American Diagnostica) that cross-reacted with rabbit von Willebrand factor. The antibody was labeled with 1251 by the IODOGEN procedure (Pierce), affinity-purified on a human von Willebrand factor-Sepharose column, and adsorbed with plasma from a patient with severe von Willebrand disease to remove traces of non-von Willebrand-specific antibody.
Immulon II microtiter strips (Dynatech) were incubated for 18 hours at 370 C with unlabeled antibody and diluted 1:400 in 0.1 M NaHCO3 (pH 9). The wells were washed twice with 10 mM Na phosphate (pH 7.4), 0.15 M NaCl (phosphate-buffered saline [PBS]), and 0.1% BSA; blocked for 20 minutes with 0.5% fatty acid-free BSA (Sigma) and 0.5% dry milk; and washed with 0.1% BSA, 0.05% Tween-20, and PBS. Serial dilutions of 5% rabbit plasma, made with PBS and 1% BSA, were incubated in the antibody-coated wells for 2 hours at 370 C with 30,000 cpm of 125I-F(ab')2 per well. Assayed concentrations of individual rabbit von Willebrand factor levels were calculated from a log-logit standard curve derived from values obtained from pooled rabbit plasma. A linear log-logit plot of percent bound antigen versus dilution was obtained when pooled rabbit plasma was diluted from 1:40 to 1:320. This amount of antigen , all separated on ME agarose gels as described in "Methods." Abscissa represents distance run in gel from top (cathodal margin) to bottom (anodal margin). Vertical dashed line represents gelposition of multimers with peak optical density in NHP standard. Highmolecular-weight multimers were defined as those larger than multimers at peak optical density of NHP.
antigen was not determined at the edge of assay sensitivity, and rabbit antigen levels in a range of 50-200% of pooled rabbit plasma could easily be assessed. Rabbit von Willebrand factor was the only protein detected by this labeled antibody (see below) when rabbit plasma was separated on SDS-agarose gels, indicating that the antibody does not cross-react with other rabbit proteins. To analyze von Willebrand factor multimer distribution (n = 14), rabbit plasma was diluted 1:1 with Veronal-buffered saline (0.28 M Na barbital and 0.125 M PBS [pH 7.4]). The samples were then mixed 1:1 with 8 M urea, 0.02 M Tris HCl (pH 8.0), 2 mM acid EDTA, and 2% SDS and heated to 600 C for 15
minutes. An aliquot of 10 gl was applied to an lxl18-cm 1% ME agarose gel (F.M.C.) containing 0.04 M Tris, 0.02 M Na acetate, and 0.02 M disodium EDTA (pH 7.4). The samples were electrophoresed at 100 V for 4 hours. After electrophoresis, the gel was fixed in 10% acetic acid and 10% isopropanol, washed twice with water, and washed once with 0.036 M borate (pH 7.85) and 0.17 M PBS containing 1 mg BSA/ml (BBS). The gel was incubated for 18 hours with BBS containing 50,000 cpm/ml 125I-F(ab')2, washed twice with 0.5 M PBS, washed three times with 0.15 M PBS, and washed once with 2% glycerol and 10% acetic acid. After drying, the gel was exposed to X-Omat AR radiographic film (Kodak, Rochester, N.Y.) for 2-4 days at -70°C in a cassette with Chronex intensifying screens (DuPont, Wilmington, Del.).
The distribution of von Willebrand factor multimers was assessed by densitometry as described previously.9"10 The von Willebrand factor of pooled human plasma was used as the standard to analyze the distribution of rabbit von Willebrand factor multimers. High-molecular-weight multimers were defined as all von Willebrand factor multimers with a size greater than multimers at the peak optical density of an autoradiograph of human plasma (Figure 2 ). To devise a numerical expression of highmolecular weight von Willebrand factor content, densitometric profiles of autoradiographs were aligned so that the fifth and sixth lower-molecularweight multimer bands of rabbit plasma were in register with those of the human control plasma. The position of the optical density profile that encompassed multimers with molecular weights of more than those at the peak was calculated. This area was then divided by the total area of the multimer profile to yield a high-molecular-weight multimer ratio. A normalized high-molecular-weight ratio was derived by dividing the ratio determined for a given rabbit of high-molecular-weight multimers to total multimers by the ratio determined for pooled normal human plasma. For example, if the ratio of high-molecularweight multimers was 0.45 for the experimental rabbit and 0.3 for the pooled normal human sample, the normalized high-molecular-weight multimer ratio for the rabbit would be 1.5.
Statistics
Statistical analyses for differences within groups were performed by one-way analysis of variance, and a Newman-Keuls test was used to determine significance. Statistical analysis for differences between groups was 1,100 1,105 ASA, aspirin; SK, streptokinase; NS, normal saline; x, observer was blinded; -, observer was not blinded. Figure 3 for two groups of rabbits-those receiving saline placebo after aspirin and streptokinase (i.e., those not receiving DDAVP; group 1) and those receiving DDAVP after aspirin and streptokinase (group 2). Intravenous administration of aspirin resulted in mean serum levels of 5.0+2.1 mg/dl and prolongation of the mean bleeding time significantly, essen-tially doubling the pretreatment value in each group (119+15 seconds increasing to 191±34 seconds in group 1 [p=NS] and 114±6 seconds increasing to 188±18 seconds in group 2 [p=NS]). Streptokinase infusion after aspirin treatment enhanced the bleeding time prolongation and increased the bleeding time to 592±119 seconds in group 1 (p<0.01 compared with baseline) and to 810±114 seconds in group 2 (p<0.01 compared with baseline).
DDAVP infusion significantly shortened the bleeding time in rabbits in group 2 to 302±29 seconds (p <0.01 compared with bleeding time after streptokinase). In contrast, rabbits receiving the saline infusion (group 1) did not demonstrate similar changes in bleeding time (572±79 seconds; p=NS compared with bleeding time after streptokinase). Bleeding times measured after DDAVP infusion were significantly less than those measured after saline infusion. Individual bleeding time values are given in Tables 1  and 2 , and mean+SEM bleeding times are given in Tables 3 and 4 .
Bleeding Time Prolongation and Bleeding Events
We measured bleeding events by two methods. In the first method, we identified rabbits that developed frank oozing of blood from the femoral surgical site and compared their bleeding times with those of rabbits with minimal or no oozing from the wound ( Table 5 ). Rabbits that developed oozing at the incision site had significantly longer bleeding times than those that did not ooze. Fifteen of 16 rabbits with bleeding times of more than 6 minutes had oozing, whereas all four rabbits with bleeding times of less than 6 minutes had no oozing (p<0.001; Fisher's exact test), using the maximal bleeding times in all cases.
As a second measure of bleeding events, autopsies were performed on 28 of 40 rabbits (18 in group 1 and 10 in group 2). Retroperitoneal hemorrhage was identified in four rabbits, all of which were in group 1. Surgical procedures were not unduly lengthy or complicated in these rabbits. All of the rabbits with hemorrhagic events had peak bleeding times in excess of 360 seconds, an observation that highlights the relation between bleeding time and the severity of bleeding. Hematological Parameters Fibrinogen, hematocrit, and platelet counts for rabbits in groups 1 and 2 are listed in Tables 3 and 4 , and average fibrinogen levels are given in Figure 4 . As seen in the tables, fibrinogen decreased by equal amounts in both groups (13% in group 1 and 17% in group 2 after streptokinase infusion) as did the hematocrit (10% in group 1 and 13% in group 2 after streptokinase infusion). There was no apparent correlation between the degree of fibrinogen reduction or hematocrit decrease and bleeding time prolongation or bleeding events, either on average or by individual correlation.
The time courses of the ex vivo platelet aggregation responses to ADP during aspirin and streptokinase infusions are shown in Tables 3 and 4 . There was no significant decrease in the rate of ADPinduced platelet aggregation 1 hour after aspirin administration. The subsequent infusion of streptokinase resulted in a downward trend of aggregation rates, probably due to the combined effect of the aspirin and plasmin. The administration of DDAVP resulted in no significant change in aggregation rates compared with the 60-minute streptokinase time point, suggesting that DDAVP's effect on bleeding time is not mediated by an increase in platelet aggregation. This point is further illustrated by the lack of difference in aggregation between animals receiving the saline placebo infusion (group 1) and those treated with DDAVP (group 2). von Willebrand Factor Antigen and Multimer Distribution The administration of aspirin and streptokinase resulted in no significant change in von Willebrand factor antigen levels (Tables 3 and 4 and Figure 5 ). Furthermore, the infusion of DDAVP resulted in a decrease of von Willebrand factor antigen rather than the expected increase. Although this value was not significantly different from that of rabbits receiving saline placebo, animals treated with DDAVP showed a significant decrease in von Willebrand factor antigen levels from baseline after infusion of DDAVP (p<0.05), whereas those receiving saline placebo demonstrated a trend toward a decrease.
A marked decrease in von Willebrand factor multimer size may render this factor less effective in hemostasis. Because the effect of aspirin and streptokinase on bleeding time may also have been a direct result of plasmin on multimer size with no effect on total von Willebrand factor antigen, von Willebrand factor multimer distributions were analyzed in a subset of animals. In comparing normalized multimer ratios (Tables 3 and 4 and Figure 6 ), there was a significant, progressive decrease over time from baseline values of 1.3+0.3 in group 1 and 1.4±0.1 in group 2 to identical values 60 minutes after streptokinase treatment (0.9+0.1). The infusion of normal saline resulted in a further decrease of the multimer ratio to 0.7±0.2 in group 1 (p=NS compared with the multimer ratio after streptokinase; p<0.05 versus baseline), whereas DDAVP resulted in a similar low value of the multimer ratio (p=NS compared with the multimer ratio after streptokinase;p<0.01 versus baseline). Furthermore, the multimer ratios after DDAVP or normal saline (0.9±0.1) were not significantly different. . Bar graphs of effects of aspirin (ASA), streptokinase (SK), and saline placebo or 1-desamino-8-D-arginine vasopressin (DDA VP) infusion on average plasma von Willebrand factor (vWF) multimer ratio in rabbits (*p<0.05 versus baseline; @p < 0. 01 versus baseline).
Discussion
The results of this study indicate that bleeding time is prolonged with the administration of aspirin and streptokinase in rabbits and that the degree of bleeding correlates with bleeding time rather than with reduction of fibrinogen levels. Most investigators have found that fibrinogen levels do not correlate with the degree of bleeding. One exception is Rao and coworkers,2 who reported a relation, albeit weak, between fibrinogen levels and bleeding in the Thrombolysis in Myocardial Infarction Trial, phase I. However, this relation was noted only on average and was not apparent in individual patient correlation analysis. In the rabbit model presented, we noted a correlation between bleeding time and bleeding frequency and intensity. Importantly, there essentially was no spontaneous bleeding when bleeding times were less than 6 minutes. This supports the observation of Gimple and colleagues4 that a correlation exists between spontaneous bleeding and bleeding times of 15 minutes or more in humans receiving t-PA.
In the present study, individual rabbits in both groups were treated with either 20,000, 40,000, or 60,000 IU/kg streptokinase. These different doses were used to ensure a prolongation of the bleeding time to more than 300 seconds. A potential mechanism to account for the wide range of streptokinase dose required is the existence of streptokinase-neutralizing antibodies. To test this hypothesis, we mea- 15-30 2 13 Oozing defined as spontaneous bleeding at the femoral catheterization or recurrent bleeding at sites of previously performed bleeding times. p<O.OOl. sured neutralizing titers in pretreatment plasmas of seven rabbits each from groups 1 and 2 that were treated with 40,000 IU/kg streptokinase and achieved an adequate bleeding prolongation and then compared them with titers in five rabbits requiring 60,000 IU/kg streptokinase to prolong bleeding time. We found that neutralizing titers were significantly greater in rabbits requiring 60,000 IU/kg than in those requiring 40,000 IU/kg to prolong bleeding time (65+12 versus 22+2 IU/ml plasma, respectively; p<0.01). Importantly, there was no dose-response relation observed between streptokinase dose and bleeding time. Finally, we reanalyzed the data in Tables 1 and 2 using only rabbits treated with 40,000 IU/kg streptokinase (11 in each group). This analysis showed there was prolongation of the bleeding time with streptokinase in aspirin-treated rabbits in both groups (515±104 seconds in group 1 and 917±192 seconds in group 2; p=NS) and a significant reversal to shortening of bleeding time by DDAVP compared with saline placebo (519±87 seconds in group 1 and 249±24 seconds in group 2; p =0.007).
The cause of the increase in bleeding time with streptokinase is not clear, but it may be the result of multiple factors, including decreases in fibrinogen, von Willebrand factor, platelet activity and number, hematocrit, blood viscosity, vascular integrity, and blood pressure.11-13 Although the slight increase in bleeding time after aspirin administration has been reported to be associated with inhibition of platelet cyclooxygenase,1314 the cause of the additional increase in bleeding time with streptokinase administration remains obscure. The levels of fibrinogen decrease but not to the degree that would result in an elevated bleeding time. Fibrin(ogen)-degradation products may also prolong bleeding time because they inhibit platelet aggregation, but they do so only at very high concentrations.15'6 These proteolytic products were not measured in this study, but given the relatively modest decrease in fibrinogen produced by the rabbits (perhaps related to antibodymediated resistance to this streptococcal product), the levels of degradation products generated are likely to have been modest and therefore ineffective in altering aggregation response. Plasmin generated by the action of streptokinase on plasma plasminogen may cleave receptors on the platelet surface, including glycoproteins IB and IIB/IIIA. [17] [18] [19] In addition, streptokinase may deplete the storage pool of platelets. 17 Niewiarowski and coworkers20 found that platelets incubated with plasmin became less sensitive to ADP and collagen with time. Our findings of a decrease in the rate of aggregation with streptokinase support Niewiarowski et al's results. These effects on platelet function may account for the increases in bleeding time with streptokinase and aspirin; however, no reversal of aggregation response occurred after DDAVP administration, thereby making unlikely a central role for platelets in the reversal of prolonged bleeding time produced by DDAVP. This view must be tempered by the caution that we used only one concentration of ADP (10 lxM) because of the limited availability of PRP. Testing aggregation with lower concentrations of ADP may have revealed differences between groups 1 and 2, given the sensitivity of rabbit platelets to even low concentrations of fibrinogen.
Although von Willebrand factor antigen levels did not change significantly with time after aspirin and streptokinase infusions, the proportion of high-molecular-weight multimers decreased. Several investigators have reported similar observations.21'23 In contrast, Hamilton and coworkers24 noted an increase in von Willebrand factor in vivo produced by plasmin over time and a decrease in vitro. They concluded that streptokinase causes a release of von Willebrand factor from Weibel-Palade bodies of the endothelial cell or secretory granules from the platelets. They also noted that patients who received streptokinase for prolonged periods of time had subsequent decreases in these elevated levels of von Willebrand factor antigen and high-molecular-weight multimers. In contrast to these results, our findings may be explained by the higher dose of streptokinase used (threefold to sixfold greater in our rabbits than that used in Hamilton et al's experiment in humans). This may have resulted in prompt plasmin digestion of von Willebrand factor released from either source. [21] [22] [23] [24] Our findings suggest that administration of DDAVP does not increase levels of fibrinogen, von Willebrand factor antigen, high-molecular-weight von Willebrand factor multimers, or platelet response to ADP to account for the reversal of prolonged bleeding time. Interestingly, DDAVP has previously been shown to be a weak antagonist of aggregation responses. 25 Coupled with the continued effect of plasmin20 and aspirin'4 on platelets, these multiple antiplatelet effects may have resulted in the progressive decrease in the rate of aggregation noted after DDAVP demonstration. DDAVP decreases bleeding time in victims of many diseases of hemostasis, including von Willebrand's disease and congenital platelet defects. If the primary defect is low von Willebrand factor (as in some forms of von Willebrand's disease), given the rapidity of the response, DDAVP must cause a release of von Willebrand factor from endothelial or platelet stores. It has been shown that in von Willebrand's disease, the improvement in skin bleeding time is temporally related to an increase in von Willebrand factor.26,27 Given the rapidity of bleeding time reversal after DDAVP, release of preformed factor(s) is more likely than new synthesis. This observation could explain why DDAVP corrects so many hemostatic abnormalities, the primary defect in which is not the lack of von Willebrand factor, such as uremic or congenital platelet defects.10,27-31 However, in the present experiments, neither von Willebrand factor antigen nor high-molecular-weight multimers increased significantly with DDAVP relative to the 60-minute streptokinase time point, suggesting an involvement in this beneficial hemostatic effect of either a selective increase in the vectorial release of von Willebrand factor into the subendothelial space (in which its levels cannot be readily measured) or factors other than von Willebrand factor. Cattaneo and colleagues32 have recently reported data that support this conclusion.
Although the treatment of myocardial infarction with thrombolytic agents has improved mortality rates, it is frequently accompanied by bleeding. DDAVP has been associated with myocardial infarction in a patient with von Willebrand's disease33; however, this patient had not been treated with thrombolytics. DDAVP may serve as an agent to control hemostasis in bleeding patients treated with thrombolytics or prophylactically in thrombolytic regimens. In an era of understandable reluctance to administer blood products, this therapeutic approach may be a useful and important alternative.
